Embecta (EMBC) Competitors

LivaNova (NASDAQ:LIVN) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

Do insiders & institutionals have more ownership in LIVN or EMBC?

97.6% of LivaNova shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 0.3% of LivaNova shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is LIVN or EMBC more profitable?

Embecta has a net margin of 5.25% compared to LivaNova's net margin of 1.91%. LivaNova's return on equity of 13.81% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	1.91%	13.81%	7.07%
Embecta	5.25%	-19.22%	11.92%

Does the media prefer LIVN or EMBC?

In the previous week, LivaNova had 12 more articles in the media than Embecta. MarketBeat recorded 17 mentions for LivaNova and 5 mentions for Embecta. Embecta's average media sentiment score of 1.38 beat LivaNova's score of 1.33 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	12 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, LIVN or EMBC?

Embecta has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.28B	1.87	$17.55M	-$4.09	-10.67
Embecta	$1.08B	0.67	$78.30M	$0.90	13.72

Which has more risk and volatility, LIVN or EMBC?

LivaNova has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Does the MarketBeat Community favor LIVN or EMBC?

LivaNova received 408 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 5.56% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
LivaNova	Outperform Votes 409 69.80%	Underperform Votes 177 30.20%
Embecta	Outperform Votes 1 5.56%	Underperform Votes 17 94.44%

Do analysts rate LIVN or EMBC?

LivaNova presently has a consensus target price of $59.29, indicating a potential upside of 35.79%. Embecta has a consensus target price of $20.33, indicating a potential upside of 64.64%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

LivaNova beats Embecta on 11 of the 19 factors compared between the two stocks.